Presentations & Publications
Recent Presentations & Publications
- Bio-Path Corporate Presentation January – 2020
- STONEGATE Capital Partners December 4, 2019 Report
- H.C. Wainwright / BPTH: Safety Testing of Phase 2 AML Trial Completed; Financing Closed; Reiterate Buy; Adjusting PT to $25
- Webcast Link to Second Quarter 2019 Financial Results – Thursday, August 15, 2019 at 8:30 a.m. ET
- Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) – January 2019
- Stonegate Capital Partners Research Report - August 2018
- BP1001 phase I-Ib protocol
- Drug Development and Delivery Published Article: DNA THERAPEUTICS - DNAbilize-ING Antisense
- Published Article: Evolution of Antisense Oligonucleotides in Oncology
- Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01
- OncLive interview with Dr. Cortes on BP-100.01 in Patients with Relapsed/Refractory AML
- Bio-Path Hopes to Blaze Profitable Path With Antisense Drugs - January 2016